Mitochondrial Peptide Research: MOTS-c, SS-31 (Elamipretide) and NAD+
Mitochondrial peptides are short peptides that either originate from mitochondrial DNA, such as MOTS-c and humanin, or are synthetic peptides designed to localize to the inner mitochondrial membrane, such as the tetrapeptide SS-31 (elamipretide).
Published work on MOTS-c is largely preclinical and examines metabolic signaling and the AMPK pathway in cells and rodents, while SS-31 has been examined for its affinity for cardiolipin in the inner membrane and has also been evaluated in registered clinical trials in primary mitochondrial disease, with mixed published results.
NAD+ is not a peptide but a redox cofactor central to the same bioenergetic literature, which is why NAD+ and NAD+ precursors appear alongside these peptides in mitochondrial research. None of the compounds described here is an approved drug for the uses discussed, and nothing on this page should be read as evidence of safety or effectiveness in humans. All products referenced on this site are supplied for in-vitro laboratory research use only. They are not drugs, foods, cosmetics or medical devices, and they are not for human or veterinary consumption or administration.
Two distinct families under one label
The phrase mitochondrial peptide covers two groups that share a compartment and little else. The first is the mitochondrially derived peptides, short open reading frames encoded within mitochondrial DNA rather than the nuclear genome. MOTS-c and humanin are the two most cited members, and the research question attached to them is whether the mitochondrion communicates outward to the nucleus and to distant tissues using peptides of its own.
The second group is synthetic and defined by where it goes rather than where it came from. SS-31, also known as elamipretide, belongs to a series of aromatic-cationic tetrapeptides whose alternating charged and aromatic residues drive accumulation at the inner mitochondrial membrane independent of membrane potential. The design goal in that literature is localization, and the experiments follow from it: what happens to membrane architecture and respiration when a peptide concentrates there.
Applied to specific lots, this is what you will see on the documentation for MOTS-c (Mitochondrial ORF of the 12S rRNA-c) 10MG, SS-31 (Elamipretide / Bendavia) 10MG, β-Nicotinamide Adenine Dinucleotide (NAD+) 500MG and NAD+ + MOTS-c + Elamipretide (SS-31) Research Kit NAD+ + MOTS-c + SS-31.
What the MOTS-c literature actually measures
MOTS-c is a 16-residue peptide encoded in the mitochondrial 12S rRNA region. Published studies are dominated by cell culture and rodent work, and the recurring readouts are AMP-activated protein kinase activation, folate and one-carbon metabolite pools, transcriptional responses in the nucleus, and metabolic parameters such as glucose tolerance in mice. A separate observational thread measures circulating MOTS-c in humans and reports associations with exercise and with age, which are correlations rather than demonstrations of causal effect.
For laboratory purposes the identity data matters more than the narrative. MOTS-c is a defined sequence with a calculated mass, so a lot is qualified the same way any other peptide lot is: reverse-phase HPLC area percent for purity, mass spectrometry against the theoretical mass for identity, and water and net peptide content before any concentration is calculated.
The Lab Notes that work through this in more detail are Storing Lyophilized Peptides Long-Term and Peptide Reconstitution Basics.
What the SS-31 and elamipretide literature actually measures
Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane, where it organizes respiratory chain supercomplexes. The SS-31 literature centers on its association with cardiolipin and the downstream structural consequences examined by electron microscopy, by extracellular flux respirometry, and by reactive oxygen species reporters in isolated mitochondria and in cell models of ischemia, kidney injury and heart failure.
Elamipretide is unusual among research peptides in also having registered clinical trial literature, including studies in primary mitochondrial myopathy and in Barth syndrome listed on ClinicalTrials.gov. Reading that literature honestly means reading the endpoints: several trials did not meet their primary endpoints, and the compound is not approved for the indications studied. A clinical program is evidence of serious investigation, not of established benefit.
NAD+ as the cofactor the peptide work keeps returning to
Nicotinamide adenine dinucleotide is the electron carrier that links substrate oxidation to the electron transport chain, and it is consumed as a substrate by sirtuins, PARPs and CD38. Because of that dual role, its abundance is treated in the literature as a readout of metabolic state rather than as an inert background quantity, and declining tissue NAD+ in aged model organisms is one of the most replicated observations in the field.
Research materials in this area include NAD+ itself and the precursors nicotinamide riboside and nicotinamide mononucleotide, which are studied on salvage pathway logic. Human trial evidence in this area is far younger than the preclinical evidence and has produced inconsistent results across small studies, so precursor work should be cited as an active question rather than a settled one.
Designing a comparison between these compounds
Because MOTS-c and SS-31 act at different layers, a comparison is only interpretable when the readout is shared. Respirometry, mitochondrial membrane potential and reactive oxygen species assays can be run on both; AMPK phosphorylation is informative for MOTS-c and largely irrelevant for SS-31. Vehicle control matters as well: the diluent, its preservative content if any, and residual counterion reported on the certificate of analysis are all variables in a mitochondrial assay.
Handling is the other controlled variable. These are lyophilized materials stored dry and cold, reconstituted immediately before use, aliquoted so the stock is not cycled through freeze and thaw, and calculated from net peptide content rather than labeled vial mass. All products referenced on this site are supplied for in-vitro laboratory research use only. They are not drugs, foods, cosmetics or medical devices, and they are not for human or veterinary consumption or administration.
Common questions
What are mitochondrial peptides?
Mitochondrial peptides are short peptides connected to mitochondrial biology in one of two ways. Mitochondrially derived peptides, including MOTS-c and humanin, are encoded within mitochondrial DNA itself and studied as signaling molecules. Mitochondria-targeted synthetic peptides, including SS-31 (elamipretide), are designed so that their charge and aromatic residues concentrate them at the inner mitochondrial membrane. Both groups are research reference materials, not approved medicines.
What is MOTS-c studied for?
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded in mitochondrial DNA. The published literature is predominantly preclinical and examines its role in metabolic signaling, AMP-activated protein kinase (AMPK) activation, nuclear gene expression responses to metabolic stress, skeletal muscle physiology in rodent models, and its behavior as a circulating peptide measured in exercise and aging studies. These are experimental findings in cells and animals, not demonstrated clinical outcomes in humans.
What is SS-31 or elamipretide?
SS-31, also called elamipretide or MTP-131, is a synthetic aromatic-cationic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) studied for its association with cardiolipin, a phospholipid specific to the inner mitochondrial membrane. Preclinical studies examine cristae structure, electron transport chain organization and reactive oxygen species handling. Elamipretide has also been evaluated in registered human clinical trials in primary mitochondrial myopathy and Barth syndrome; published trial results have been mixed and it is not an approved treatment for the indications studied.
How does MOTS-c research differ from SS-31 research?
They occupy different layers of mitochondrial biology, so the experiments look different. MOTS-c is studied as an endogenous signaling peptide: typical readouts are AMPK phosphorylation, metabolic gene expression, glucose handling in rodent models and circulating peptide concentration. SS-31 is studied as a structural and bioenergetic agent at the inner membrane: typical readouts are cardiolipin binding, cristae morphology by electron microscopy, respiration measured with extracellular flux analysis and reactive oxygen species assays. MOTS-c work is almost entirely preclinical; SS-31 additionally has clinical trial literature.
How is NAD+ related to mitochondrial research?
Nicotinamide adenine dinucleotide (NAD+) is the redox cofactor that carries electrons into the electron transport chain and a substrate for sirtuins and PARP enzymes. Research interest centers on the observation that NAD+ concentration and the NAD+/NADH ratio change with metabolic state and with age in model systems, which is why NAD+ and its precursors nicotinamide riboside and nicotinamide mononucleotide appear throughout bioenergetics work. NAD+ is a cofactor rather than a peptide, and human trial evidence for the outcomes often discussed publicly remains limited and inconsistent.
Does preclinical mitochondrial research transfer to humans?
Frequently it does not. Cell culture uses concentrations and exposure times chosen for measurability, rodent models differ from human physiology in metabolic rate and lifespan, and peptide pharmacokinetics differ between species. The correct reading of a positive preclinical result is that a mechanism is plausible enough to test further, not that an effect exists in people. Laboratory documentation should keep cell, animal and clinical evidence in separate columns.
Sources
Primary standards, regulatory guidance and reference data. Links open in a new tab.
- PubMed — MOTS-c mitochondrial derived peptide literatureNational Library of Medicine
- PubMed — elamipretide / SS-31 cardiolipin literatureNational Library of Medicine
- ClinicalTrials.gov — registered elamipretide studiesU.S. National Library of Medicine
- PubChem — nicotinamide adenine dinucleotide (NAD+) compound recordNational Center for Biotechnology Information
- National Institute on Aging — research on aging biologyNational Institutes of Health
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.
